{"id":995029,"date":"2026-08-13T12:54:24","date_gmt":"2026-08-13T16:54:24","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/sion-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-sionna-therapeutics\/"},"modified":"2026-08-13T12:54:24","modified_gmt":"2026-08-13T16:54:24","slug":"sion-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-sionna-therapeutics","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/sion-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-sionna-therapeutics\/","title":{"rendered":"SION SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Sionna Therapeutics"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n Sionna Therapeutics shares traded above $44 in July 2026; after the SION-719 Phase 2a readout, roughly 90% of that value was lost. SueWallSt notifies investors of a pending investigation into potential securities law violations, and SION investors who lost money have legal rights worth reviewing now. <\/i>\n <\/p>\n

\n NEW YORK<\/span>, Aug. 13, 2026<\/span> \/PRNewswire\/ — Shareholders of Sionna Therapeutics (NASDAQ: SION) watched approximately 90% of the stock’s value disappear following the Company’s disclosure that its Phase 2a PreciSION CF trial of SION-719 failed to achieve its key activity endpoint for sweat chloride reduction. If you held SION shares and suffered a loss, you have rights and a limited window to assert them — click here to submit your information <\/a>. You may also contact Joseph E. Levi, Esq. via email at jlevi@SueWallSt.com <\/a>\u00a0or by telephone at (888) SueWallSt.<\/p>\n

\n

\n \"SueWallSt.com\"\n <\/p>\n<\/p><\/div>\n

Investors do not need to still own SION shares to participate. Eligibility in the investigation is based on when shares were purchased and the losses sustained — not on whether the position was sold before or after the readout. There is no minimum loss amount, and submitting information carries no cost and no obligation.<\/p>\n

The reported result was a placebo-adjusted sweat chloride change of -1.0 mmol\/L (p=0.7), and Sionna stated it would not advance SION-719 as an add-on therapy. Shareholders who wish to understand what recovery options may be available, and how their own purchase records factor in, can have their losses reviewed at no charge.<\/p>\n

SION shareholders who lost money are encouraged to have their losses evaluated at no cost <\/a>\u00a0or call (888) SueWallSt.<\/p>\n

\n WHY SUEWALLST <\/b>: SueWallSt is powered by Levi & Korsinsky LLP. Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.<\/p>\n

Frequently Asked Questions About the SION Investigation<\/p>\n

\n Q: Who is eligible to participate in the SION investigation? <\/b>\u00a0A: Investors who purchased SION stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses — not on whether you still hold the shares.<\/p>\n

\n Q: How much did SION stock drop? <\/b>\u00a0A: Shares fell approximately 90% after the Company disclosed that the Phase 2a PreciSION CF trial of SION-719failed to achieve its key activity endpoint for sweat chloride reduction and that it would not advance SION-719 as an add-on therapy. Investors who purchased shares and suffered losses may be eligible to seek compensation.<\/p>\n

\n Q: When did Sionna Therapeutics allegedly<\/span> mislead investors? <\/b>\u00a0A: The investigation concerns statements made before the corrective disclosure that allegedly<\/span> caused investors to purchase securities at inflated prices.<\/p>\n

\n Q: What if I already sold my SION shares — can I still recover losses? <\/b>\u00a0A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought SION and sold at a loss may still participate in the investigation.<\/p>\n

\n Q: What if my SION losses are small — is it still worth contacting a lawyer? <\/b>\u00a0A: Yes. There is no minimum loss amount required to participate in the investigation.<\/p>\n

\n Q: Do I need to go to court or give testimony? <\/b>\u00a0A: No. Participating in the investigation does not require court appearances or depositions. If legal action is later pursued, the overwhelming majority of affected investors never appear in court either.<\/p>\n

\n Q: What if I live outside the United States? <\/b>\u00a0A: U.S. securities fraud<\/span> investigations generally cover purchases on U.S. exchanges regardless of the investor’s country of residence.<\/p>\n

\n Q: What do SION investors need to do right now? <\/b>\u00a0A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact SueWallSt, a brand of Levi & Korsinsky LLP, for a no-cost, no-obligation evaluation at jlevi@levikorsinsky.com <\/a>\u00a0or (212) 363-7500. No immediate action is required to remain eligible to participate in the investigation.<\/p>\n

CONTACT:\\<\/p>\n

Levi & Korsinsky, LLP\\<\/p>\n

Joseph E. Levi, Esq.\\<\/p>\n

33 Whitehall Street, 27th Floor\\<\/p>\n

New York, NY 10004\\<\/p>\n

\n jlevi@SueWallSt.com <\/a>\\<\/p>\n

Tel: (888) SueWallSt\\<\/p>\n

Fax: (212) 363-7171<\/p>\n

Attorney Advertising. Prior results do not guarantee similar outcomes.<\/p>\n

\n \"Cision\" View original content to download multimedia:https:\/\/www.prnewswire.com\/news-releases\/sion-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-sionna-therapeutics-302851168.html<\/a><\/p>\n

SOURCE SueWallSt.com<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire Sionna Therapeutics shares traded above $44 in July 2026; after the SION-719 Phase 2a readout, roughly 90% of that value was lost. SueWallSt notifies investors of a pending investigation into potential securities law violations, and SION investors who lost money have legal rights worth reviewing now. NEW YORK, Aug. 13, 2026 \/PRNewswire\/ — Shareholders of Sionna Therapeutics (NASDAQ: SION) watched approximately 90% of the stock’s value disappear following the Company’s disclosure that its Phase 2a PreciSION CF trial of SION-719 failed to achieve its key activity endpoint for sweat chloride reduction. If you held SION shares and suffered a loss, you have rights and a limited window to assert them — click here to submit your information . … <\/p>\n

Continue reading “SION SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Sionna Therapeutics”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-995029","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSION SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Sionna Therapeutics - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sion-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-sionna-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SION SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Sionna Therapeutics - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire Sionna Therapeutics shares traded above $44 in July 2026; after the SION-719 Phase 2a readout, roughly 90% of that value was lost. SueWallSt notifies investors of a pending investigation into potential securities law violations, and SION investors who lost money have legal rights worth reviewing now. NEW YORK, Aug. 13, 2026 \/PRNewswire\/ — Shareholders of Sionna Therapeutics (NASDAQ: SION) watched approximately 90% of the stock’s value disappear following the Company’s disclosure that its Phase 2a PreciSION CF trial of SION-719 failed to achieve its key activity endpoint for sweat chloride reduction. If you held SION shares and suffered a loss, you have rights and a limited window to assert them — click here to submit your information . … Continue reading "SION SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Sionna Therapeutics"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/sion-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-sionna-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-13T16:54:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mmx.prnewswire.com\/media\/MS1812443\/suewallst-logo-1-Logo.jpg?id=OA2882505\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sion-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-sionna-therapeutics\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sion-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-sionna-therapeutics\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"SION SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Sionna Therapeutics\",\"datePublished\":\"2026-08-13T16:54:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sion-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-sionna-therapeutics\\\/\"},\"wordCount\":751,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sion-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-sionna-therapeutics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS1812443\\\/suewallst-logo-1-Logo.jpg?id=OA2882505\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sion-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-sionna-therapeutics\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sion-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-sionna-therapeutics\\\/\",\"name\":\"SION SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Sionna Therapeutics - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sion-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-sionna-therapeutics\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sion-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-sionna-therapeutics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS1812443\\\/suewallst-logo-1-Logo.jpg?id=OA2882505\",\"datePublished\":\"2026-08-13T16:54:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sion-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-sionna-therapeutics\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sion-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-sionna-therapeutics\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sion-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-sionna-therapeutics\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS1812443\\\/suewallst-logo-1-Logo.jpg?id=OA2882505\",\"contentUrl\":\"https:\\\/\\\/mmx.prnewswire.com\\\/media\\\/MS1812443\\\/suewallst-logo-1-Logo.jpg?id=OA2882505\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sion-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-sionna-therapeutics\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SION SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Sionna Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SION SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Sionna Therapeutics - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/sion-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-sionna-therapeutics\/","og_locale":"en_US","og_type":"article","og_title":"SION SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Sionna Therapeutics - Market Newsdesk","og_description":"PR Newswire Sionna Therapeutics shares traded above $44 in July 2026; after the SION-719 Phase 2a readout, roughly 90% of that value was lost. SueWallSt notifies investors of a pending investigation into potential securities law violations, and SION investors who lost money have legal rights worth reviewing now. NEW YORK, Aug. 13, 2026 \/PRNewswire\/ — Shareholders of Sionna Therapeutics (NASDAQ: SION) watched approximately 90% of the stock’s value disappear following the Company’s disclosure that its Phase 2a PreciSION CF trial of SION-719 failed to achieve its key activity endpoint for sweat chloride reduction. If you held SION shares and suffered a loss, you have rights and a limited window to assert them — click here to submit your information . … Continue reading \"SION SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Sionna Therapeutics\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/sion-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-sionna-therapeutics\/","og_site_name":"Market Newsdesk","article_published_time":"2026-08-13T16:54:24+00:00","og_image":[{"url":"https:\/\/mmx.prnewswire.com\/media\/MS1812443\/suewallst-logo-1-Logo.jpg?id=OA2882505","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sion-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-sionna-therapeutics\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sion-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-sionna-therapeutics\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"SION SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Sionna Therapeutics","datePublished":"2026-08-13T16:54:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sion-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-sionna-therapeutics\/"},"wordCount":751,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sion-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-sionna-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/mmx.prnewswire.com\/media\/MS1812443\/suewallst-logo-1-Logo.jpg?id=OA2882505","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sion-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-sionna-therapeutics\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/sion-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-sionna-therapeutics\/","name":"SION SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Sionna Therapeutics - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sion-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-sionna-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sion-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-sionna-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/mmx.prnewswire.com\/media\/MS1812443\/suewallst-logo-1-Logo.jpg?id=OA2882505","datePublished":"2026-08-13T16:54:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sion-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-sionna-therapeutics\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/sion-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-sionna-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sion-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-sionna-therapeutics\/#primaryimage","url":"https:\/\/mmx.prnewswire.com\/media\/MS1812443\/suewallst-logo-1-Logo.jpg?id=OA2882505","contentUrl":"https:\/\/mmx.prnewswire.com\/media\/MS1812443\/suewallst-logo-1-Logo.jpg?id=OA2882505"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sion-shareholder-investigation-suewallst-notifies-investors-of-potential-securities-claims-involving-sionna-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"SION SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Sionna Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/995029","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=995029"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/995029\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=995029"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=995029"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=995029"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}